Last reviewed · How we verify
NanO2TM
At a glance
| Generic name | NanO2TM |
|---|---|
| Also known as | Dodecafluoropentane emulsion (DDFPe) |
| Sponsor | NHS Greater Glasgow and Clyde |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM (PHASE2)
- NanO2 in Large VessEL Occlusion Stroke (NOVEL) (PHASE2)
- A Phase Ib/II in Patients With Acute Ischemic Stroke (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NanO2TM CI brief — competitive landscape report
- NanO2TM updates RSS · CI watch RSS
- NHS Greater Glasgow and Clyde portfolio CI